VRDN Projected Dividend Yield
Viridian Therapeutics Inc ( NASDAQ : VRDN )Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. Co. is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). Co. is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. 21 YEAR PERFORMANCE RESULTS |
VRDN Dividend History Detail VRDN Dividend News VRDN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |